PKCs: Pernicious kinase culprits in acetaminophen pathogenesis
Cynthia Ju, Robert A. Roth – 8 November 2013
Application of complement component 4d immunohistochemistry to ABO‐compatible and ABO‐incompatible liver transplantation
Adeeb Salah, Masakazu Fujimoto, Atsushi Yoshizawa, Kimiko Yurugi, Aya Miyagawa‐Hayashino, Shinji Sumiyoshi, Sachiko Minamiguchi, Shinji Uemoto, Taira Maekawa, Hironori Haga – 6 November 2013 – Antibody‐mediated rejection (AMR) is difficult to diagnose after ABO‐compatible or ABO‐identical (ABO‐C) liver transplantation. To determine whether complement component 4d (C4d) immunostaining would be useful for diagnosing AMR, we compared the results of C4d immunohistochemistry for allograft biopsy samples with assays for anti‐donor antibodies performed at the time of biopsy.
Antibody‐mediated rejection as a contributor to previously unexplained early liver allograft loss
Jacqueline G. O'Leary, Hugo Kaneku, Anthony J. Demetris, John D. Marr, S. Michelle Shiller, Brian M. Susskind, Glenn W. Tillery, Paul I. Terasaki, Göran B. Klintmalm – 6 November 2013 – We analyzed 60 patients with idiopathic early allograft loss (defined as death or retransplantation at <90 days) to determine the relative contribution of preformed donor‐specific human leukocyte antigen alloantibodies (DSAs) to this endpoint, and we defined strict criteria for the diagnosis of antibody‐mediated rejection (AMR) in liver allografts.
Functional distal splenorenal shunt and splenic artery ligation as portal flow modulation in left lobe living donor transplantation
Jay A. Graham, Benjamin Samstein, Jean C. Emond, Tomoaki Kato – 6 November 2013
Neurocognitive function and dysfunction after hepatitis C therapy
Pablo Solis‐Muñoz, Carlos Mingote‐Adán, Jose Antonio Solís‐Herruzo – 1 November 2013
Reply
Ho Cheol Hong, Kyung Mook Choi – 1 November 2013
Reply
Arne Schäfer, Michael R. Kraus, Michael Scheurlen – 31 October 2013
Introducing the AASLD President: Adrian Di Bisceglie
Jay H. Hoofnagle – 31 October 2013
Presence of sarcopenia (muscle wasting) in patients with nonalcoholic steatohepatitis
Danny Issa, Naim Alkhouri, Cynthia Tsien, Shetal Shah, Rocio Lopez, Arthur McCullough, Srinivasan Dasarathy – 31 October 2013
Prerecovery liver biopsy in the brain‐dead donor: A case‐control study of logistics, safety, precision, and utility
Joseph Benton Oliver, Stephen Peters, Advaith Bongu, Abdel‐Kareem Beidas, George Dikdan, Lloyd Brown, Baburao Koneru – 31 October 2013 – Prerecovery liver biopsy (PLB) can potentially to decrease futile recovery and increase utilization of marginal brain‐dead donor (BDD) livers. A case‐control study was conducted to examine the logistics, safety, histological precision, and liver utilization associated with PLB in BDDs. Twenty‐three cases between January 2008 and January 2013 were compared to 2 groups: 48 sequential and 69 clinically matched controls.